ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
데노수맙 시장 규모는 최근 빠르게 확대하고 있습니다. 2025년 36억 7,000만 달러에서 2026년에는 40억 6,000만 달러로, CAGR 10.7%로 성장할 것으로 예상됩니다. 지난 수년간의 성장에는 골다공증 및 뼈 관련 질환의 높은 유병률, 고령 인구의 증가, 데노수맙 치료제의 조기 승인, 병원 및 전문 클리닉의 수용력 확대, 환자들의 골절 위험에 대한 인식 증가 등이 주요 요인으로 꼽힙니다.
데노수맙 시장 규모는 향후 몇 년간 급속한 성장이 전망됩니다. 2030년에는 60억 6,000만 달러에 달하고, CAGR은 10.5%가 될 전망입니다. 예측 기간 동안의 성장 요인으로는 정밀의료 및 생물학적 제제의 발전, 재택의료 및 외래진료 서비스 확대, 뼈 건강 연구에 대한 투자 증가, 차세대 데노수맙 제제 도입, 신흥 시장에서의 수요 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 단클론항체 채용 확대, 골다공증 스크리닝 프로그램 확대, 골 전이에 대한 개별화된 치료 접근법, 재택 주사 요법의 성장, 고령화 사회에서의 뼈 건강에 대한 인식 증가 등을 들 수 있습니다.
골다공증 유병률 증가는 향후 몇 년간 데노수맙 시장 성장을 견인할 것으로 예상됩니다. 골다공증은 뼈가 약해지는 질환으로 골밀도가 낮아지고 골절 위험이 증가하는 질환입니다. 데노수맙은 RANK 리간드를 표적으로 하여 골흡수를 억제함으로써 골다공증 치료에 사용됩니다. 예를 들어, 2023년 9월 미국 정부 기관인 국립생물공학정보센터가 발표한 자료에 따르면, 캐나다 노인 종단연구에서 지역 거주 고령 여성의 의사 진단 골다공증 유병률은 12.7%, DXA 검사로 확인된 골다공증 유병률은 5.9%로 나타났습니다. 또한 Buttros 등은 골밀도(BMD) 측정으로 진단한 횡단 연구를 통해 40-75세 폐경 후 여성의 골다공증 유병률이 24.6%에 달한다는 사실을 밝혀냈습니다. 따라서 골다공증 유병률의 증가는 데노수맙 시장의 성장을 촉진하고 있습니다.
헬스케어 산업의 성장은 데노수맙 시장의 추가 확장을 촉진할 것으로 예상됩니다. 헬스케어 산업은 의료 서비스 제공, 치료법 개발, 그리고 인간의 건강을 유지 및 개선하기 위한 제품 및 기술 공급을 포괄합니다. 이 분야는 고령화와 세계 인구 증가에 따른 의료 서비스 수요 증가로 인해 확대되고 있습니다. 데노수맙은 골다공증 및 암 관련 골감소증에 대한 효과적인 치료법을 제공하고 환자들의 예후를 개선함으로써 헬스케어 산업을 뒷받침하고 있습니다. 예를 들어, 2023년 5월 미국 비영리단체인 미국헬스케어협회(American Health Care Association)의 발표에 따르면, 미국 내 병원 수는 2022년 6,093개에서 2023년 6,129개로 증가할 것으로 예상했습니다. 따라서 헬스케어 산업의 확장은 데노수맙 시장의 성장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting the formation of osteoclasts, reducing bone resorption, increasing bone mineral density, and lowering the risk of fractures.
The main types of denosumab drugs include Prolia, Xgeva, and others. Prolia is a prescription medication used to treat osteoporosis in postmenopausal women who are at high risk of fractures or cannot take other osteoporosis treatments. These drugs are available in 60 mg and 120 mg doses and are used by end users such as hospitals, home care providers, specialty clinics, and ambulatory surgical centers.
Tariffs have impacted the denosumab market by increasing the cost of importing raw materials, biologics manufacturing equipment, and specialty drug components. This has affected production timelines and pricing, particularly for segments like 120 mg dosage forms and specialty clinics in regions such as Asia-Pacific and Europe. While costs have risen, some manufacturers are leveraging tariffs as an opportunity to localize production and optimize supply chains, which may improve resilience and innovation in biologics manufacturing.
The denosumab market research report is one of a series of new reports from The Business Research Company that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The denosumab market size has grown rapidly in recent years. It will grow from $3.67 billion in 2025 to $4.06 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to high prevalence of osteoporosis and bone-related disorders, growing geriatric population, early approvals of denosumab therapies, increasing hospital and specialty clinic capacities, rising awareness of fracture risk among patients.
The denosumab market size is expected to see rapid growth in the next few years. It will grow to $6.06 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to advancements in precision medicine and biologics, expansion of homecare and ambulatory services, increased investment in bone health research, introduction of next-generation denosumab formulations, rising demand in emerging markets. Major trends in the forecast period include increased adoption of monoclonal antibodies, expansion of osteoporosis screening programs, personalized treatment approaches for bone metastases, growth in home-based injection therapies, rising awareness of bone health in aging population.
The rising prevalence of osteoporosis is expected to drive the growth of the denosumab market in the coming years. Osteoporosis is a medical condition in which bones become weak, leading to reduced bone density and an increased risk of fractures. Denosumab is used to treat osteoporosis by inhibiting bone resorption through targeting the RANK ligand. For instance, in September 2023, the National Center for Biotechnology Information, a US-based government agency, reported that data from the Canadian Longitudinal Study on Aging showed a prevalence of physician-diagnosed osteoporosis of 12.7% and DXA-confirmed osteoporosis of 5.9% in females among community-dwelling older adults. Additionally, Buttros and colleagues conducted a cross-sectional study revealing a 24.6% prevalence of osteoporosis in postmenopausal women aged 40 to 75, diagnosed using bone mineral density (BMD) measurements. Therefore, the increasing prevalence of osteoporosis is fueling the growth of the denosumab market.
The growth of the healthcare industry is expected to further drive the expansion of the denosumab market. The healthcare industry encompasses the provision of medical services, the development of treatments, and the supply of products and technologies to maintain and improve human health. This sector is expanding due to rising demand for medical services driven by aging and growing global populations. Denosumab supports the healthcare industry by offering an effective therapy for osteoporosis and cancer-related bone loss, improving patient outcomes. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the number of hospitals in the US increased to 6,129 in 2023 from 6,093 in 2022. Therefore, the expansion of the healthcare industry is propelling growth in the denosumab market.
Major companies in the denosumab market are focusing on expanding global clinical trials and accelerating regulatory approvals to strengthen their competitive position and widen treatment access. Clinical trials are human-based studies that assess the effectiveness and safety of new drugs or therapies. For instance, in May 2023, Boan Biotech, a China-based biopharmaceutical company, initiated an international multicenter Phase 3 clinical trial for its denosumab biosimilars BA6101 (Boyoubei) and BA1102, enrolling the first patients in Europe, the U.S., and Japan. These efforts follow its 2022 NMPA approval for Boyoubei in postmenopausal women at high fracture risk. By advancing global clinical development and securing regulatory progress, companies reinforce their competitiveness in the denosumab market.
Major companies operating in the denosumab market are Amgen Inc., Fresenius SE & Co KGaA, Amneal Pharmaceuticals Inc., Dr Reddy's Laboratories Ltd, Biocon Ltd, Sandoz Group AG, Samsung Bioepis Co Ltd, Celltrion Inc, Organon & Co, Shanghai Henlius Biotech Inc, Teva Pharmaceutical Industries Ltd, Accord Healthcare Ltd, CuraTeQ Biologics Pvt Ltd, AryoGen Pharmed Co, BioXpress Therapeutics AG, Henlius Biotech Co Ltd, JHL Biotech Inc, Oncobiologics Inc, Teva International GmbH (Teva biosimilars unit), Hikma Pharmaceuticals PLC, Gedeon Richter Plc, Accord BioPharma Inc
North America was the largest region in the denosumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Denosumab Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses denosumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for denosumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The denosumab market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Classification: Prolia; Xgeva
2) By Type: 60 mg; 120 mg
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Ambulatory Surgical Centers
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Increased Adoption Of Monoclonal Antibodies
4.2.2 Expansion Of Osteoporosis Screening Programs
4.2.3 Personalized Treatment Approaches For Bone Metastases
4.2.4 Growth In Home-Based Injection Therapies
4.2.5 Rising Awareness Of Bone Health In Aging Population
5. Denosumab Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Homecare
5.3 Specialty Clinics
5.4 Ambulatory Surgical Centers
5.5 Others
6. Denosumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Denosumab Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Denosumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Denosumab Market Size, Comparisons And Growth Rate Analysis
7.3. Global Denosumab Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Denosumab Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Denosumab Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Denosumab Market Segmentation
9.1. Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Prolia, Xgeva
9.2. Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
>60 mg, 120 mg
9.3. Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10. Denosumab Market Regional And Country Analysis
10.1. Global Denosumab Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Denosumab Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Denosumab Market
11.1. Asia-Pacific Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Denosumab Market
12.1. China Denosumab Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Denosumab Market
13.1. India Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Denosumab Market
14.1. Japan Denosumab Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Denosumab Market
15.1. Australia Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Denosumab Market
16.1. Indonesia Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Denosumab Market
17.1. South Korea Denosumab Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Denosumab Market
18.1. Taiwan Denosumab Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Denosumab Market
19.1. South East Asia Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Denosumab Market
20.1. Western Europe Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Denosumab Market
21.1. UK Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Denosumab Market
22.1. Germany Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Denosumab Market
23.1. France Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Denosumab Market
24.1. Italy Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Denosumab Market
25.1. Spain Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Denosumab Market
26.1. Eastern Europe Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Denosumab Market
27.1. Russia Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Denosumab Market
28.1. North America Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Denosumab Market
29.1. USA Denosumab Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Denosumab Market
30.1. Canada Denosumab Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Denosumab Market
31.1. South America Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Denosumab Market
32.1. Brazil Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Denosumab Market
33.1. Middle East Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Denosumab Market
34.1. Africa Denosumab Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Denosumab Market, Segmentation By Drug Classification, Segmentation By Type, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Denosumab Market Regulatory and Investment Landscape
36. Denosumab Market Competitive Landscape And Company Profiles
36.1. Denosumab Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Denosumab Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Denosumab Market Company Profiles
36.3.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Fresenius SE & Co KGaA Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Amneal Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Dr Reddy's Laboratories Ltd Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Biocon Ltd Overview, Products and Services, Strategy and Financial Analysis
37. Denosumab Market Other Major And Innovative Companies
